Epitomee, the Israeli Capsule Aiming to Revolutionize Weight Loss
- Caroline Haïat
- 2 days ago
- 2 min read
Losing weight by simply swallowing a capsule? This is now becoming possible thanks to the groundbreaking medical advancement developed by the Israeli company Epitomee Medical, presented during the technology innovation conference held on May 6 in Tel Aviv. At a time when the global obesity market is increasingly dominated by GLP-1 injectable treatments, Epitomee Medical is taking a completely different approach: a drug-free capsule designed to create a natural feeling of fullness.
Based in Caesarea, the company specializes in technologies related to weight management and metabolic diseases. Founded by Israeli entrepreneur Shimon Eckhouse, who is also known for founding Lumenis and Syneron Medical, Epitomee Medical aims to provide a more accessible, less invasive, and non-pharmaceutical alternative to existing obesity treatments.
The biodegradable capsule is taken with two glasses of water before meals. Once it reaches the stomach, the capsule’s outer shell dissolves when exposed to the targeted pH level of the digestive system. The hydrogel particles inside then absorb surrounding fluids and gradually expand, allowing the device’s structure to deploy into its final shape.
After its active period, the structure naturally disintegrates, moves freely through the gastrointestinal tract, and is safely eliminated from the body.
One of the key technological components behind Epitomee’s solution is the use of biodegradable, organic, and pH-sensitive polymers. This design allows the company to precisely control both the duration of the device’s activity and the mechanism that initiates the end of its action, providing users with a safe and comfortable experience.
The company also emphasizes that its solution requires neither weekly injections nor surgical procedures.
Clinical trials conducted by the company have shown promising results. The reset study, carried out in the United States on overweight and obese adults, demonstrated significant weight loss among patients, along with improvements in eating behaviors and feelings of satiety.
Beyond weight loss, the technology could also have implications for the prevention of type 2 diabetes and other metabolic diseases associated with obesity.
The growing interest surrounding Epitomee Medical also reflects Israel’s increasingly important role in global medical innovation. In recent years, the country has become a major player in health technologies, particularly in medtech, digital health, and smart medical devices.
Caroline Haïat
Comments